MedaSorb has initiated its first clinical site and will be enrolling up to a total of nine sites for the European study. MedaSorb estimates the study will take between six to nine months to complete.
Al Kraus, president and CEO of MedaSorb, said: “We are excited to start our largest clinical study to date, which, if successful, could represent a major breakthrough in the fight against sepsis.”